Birdwatch Archive

Birdwatch Note

2024-05-08 03:19:50 UTC - MISINFORMED_OR_POTENTIALLY_MISLEADING

Misleading. AstraZeneca withdrew its vaccine due to lack of market demand: other vaccines tackle newer variants https://www.theguardian.com/business/article/2024/may/08/astrazeneca-withdraws-covid-19-vaccine-worldwide-citing-surplus-of-newer-vaccines Numerous studies quantify the rarity of TTS complications: https://www.bmj.com/content/374/bmj.n1931 https://www.cnbc.com/2021/08/12/blood-clots-linked-to-astrazeneca-shot-have-22percent-mortality-rate-study.html https://www.tga.gov.au/news/covid-19-vaccine-safety-reports/covid-19-vaccine-weekly-safety-report-27-01-2022 https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3886421 https://www.hdruk.ac.uk/news/two-health-data-research-uk-studies-find-only-small-elevated-risk-of-blood-clots-following-astrazeneca-covid-19-vaccination/ TTS complications were publicized & contextualized back in Mar & Jul 2021 https://www.astrazeneca.com/media-centre/press-releases/2021/update-on-the-safety-of-covid-19-vaccine-astrazeneca.html https://www.astrazeneca.com/media-centre/press-releases/2021/vaxzevria-showed-no-increased-incidence-of-thrombosis-with-thrombocytopenia-after-second-dose.html

Written by B615626EC757FF74A9C335FF03B5E142707B52279A4D659FC24FBA53727B84F8
Participant Details

All Information

• ID - 1788046123950899591
• noteId - 1788046123950899591
• participantId -
• noteAuthorParticipantId - B615626EC757FF74A9C335FF03B5E142707B52279A4D659FC24FBA53727B84F8 Participant Details
• createdAtMillis - 1715138390898
• tweetId - 1788031190194417979
• classification - MISINFORMED_OR_POTENTIALLY_MISLEADING
• believable -
• harmful -
• validationDifficulty -
• misleadingOther - 0
• misleadingFactualError - 1
• misleadingManipulatedMedia - 0
• misleadingOutdatedInformation - 0
• misleadingMissingImportantContext - 1
• misleadingUnverifiedClaimAsFact - 0
• misleadingSatire - 0
• notMisleadingOther - 0
• notMisleadingFactuallyCorrect - 0
• notMisleadingOutdatedButNotWhenWritten - 0
• notMisleadingClearlySatire - 0
• notMisleadingPersonalOpinion - 0
• trustworthySources - 1
• summary
• Misleading. AstraZeneca withdrew its vaccine due to lack of market demand: other vaccines tackle newer variants https://www.theguardian.com/business/article/2024/may/08/astrazeneca-withdraws-covid-19-vaccine-worldwide-citing-surplus-of-newer-vaccines Numerous studies quantify the rarity of TTS complications: https://www.bmj.com/content/374/bmj.n1931 https://www.cnbc.com/2021/08/12/blood-clots-linked-to-astrazeneca-shot-have-22percent-mortality-rate-study.html https://www.tga.gov.au/news/covid-19-vaccine-safety-reports/covid-19-vaccine-weekly-safety-report-27-01-2022 https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3886421 https://www.hdruk.ac.uk/news/two-health-data-research-uk-studies-find-only-small-elevated-risk-of-blood-clots-following-astrazeneca-covid-19-vaccination/ TTS complications were publicized & contextualized back in Mar & Jul 2021 https://www.astrazeneca.com/media-centre/press-releases/2021/update-on-the-safety-of-covid-19-vaccine-astrazeneca.html https://www.astrazeneca.com/media-centre/press-releases/2021/vaxzevria-showed-no-increased-incidence-of-thrombosis-with-thrombocytopenia-after-second-dose.html